Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25801535 | 0.85 | TSHR (0.31) | TSHRSMN1; SMN2 | |
| SCHEMBL5575508 | 0.84 | CYP3A4 (0.38) | TSHRCYP2C9CYP2C19CYP3A4HTT | |
| SCHEMBL25801865 | 0.84 | NOS1 (0.30) | — | |
| SCHEMBL13641265 | 0.82 | CTSS (0.32) | — | |
| SCHEMBL25801863 | 0.82 | TSHR (0.32) | TSHRSMN1; SMN2 | |
| SCHEMBL25802002 | 0.79 | MMP8 (0.33) | — | |
| SCHEMBL22207787 | 0.76 | TSHR (0.37) | TSHR | |
| SCHEMBL13269359 | 0.75 | POLB (0.38) | CYP2C9CYP2C19CYP3A4SMN1; SMN2 | |
| SCHEMBL6819825 | 0.73 | GAA (0.36) | TSHRCYP2C9CYP2C19CYP3A4SMN1; SMN2 | |
| SCHEMBL4807731 | 0.73 | GAA (0.39) | CYP2C9CYP2C19CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018111-A1 | ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2024-01-18 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | TSHR 3550/4885CYP2C9 2299/4885CYP2C19 2454/4885 |
| US-20240018111-A1 | ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | PTGS1, PTGER1, PTGES2 | TSHR 3299/4885CYP2C9 2017/4885CYP2C19 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.